nach oben

Erschienen in:

21.02.2023 | REVIEW

Safety, metabolic and psychological outcomes of Medtronic MiniMed 670G in children, adolescents and young adults: a systematic review

verfasst von: Chiara Mameli, Giulia Marie Smylie, Alessio Galati, Biagio Rapone, Roque Cardona-Hernandez, Gianvincenzo Zuccotti, Maurizio Delvecchio

Erschienen in: European Journal of Pediatrics | Ausgabe 5/2023

Einloggen, um Zugang zu erhalten

Abstract

Hybrid closed loop (HCL) systems are the combination of a pump for insulin delivery and a glucose sensor for continuous glucose monitoring. These systems are managed by an algorithm, which delivers insulin on the basis of the interstitial glucose levels. The MiniMed™ 670G system was the first HCL system available for clinical purpose. In this paper, we reviewed the literature about metabolic and psychological outcomes in children, adolescents and young adults with type 1 diabetes treated with MiniMed™ 670G. Only 30 papers responded to the inclusion criteria and thus were considered. All the papers show that the system is safe and effective in managing glucose control. Metabolic outcomes are available up to 12 months of follow-up; longer study period are lacking. This HCL system may improve HbA1c up to 7.1% and time in range up to 73%. The time spent in hypoglycaemia is almost neglectable. Better improvement in blood glucose control is observed in patients with higher HbA1c at HCL system start and larger daily use of auto-mode functionality.

Conclusion: The Medtronic MiniMed™ 670G is safe and well accepted, without any increase in the burden for patients. Some papers report an improvement in the psychological outcomes, but other papers do not confirm this finding. So far, it significantly improves the management of diabetes mellitus in children, adolescents and young adults. Proper training and support by the diabetes team are mandatory. Studies for a period longer than 1 year would be appreciated to better understand the potentiality of this system.

What is Known:

• The Medtronic MiniMed^TM 670G is a hybrid closed loop system which combines a continuous glucose monitoring sensor with an insulin pump.

• It has been the first hybrid closed loop system available for clinical purpose. Adequate training and patients support play a key role in diabetes management.

What is New:

• The Medtronic MiniMed^TM 670G may improve HbA1c and CGM metrics up to 1-year of follow-up, but the improvement appears lower than advanced hybrid closed loop systems. This system is effective to prevent hypoglycaemia.

• The psychosocial effects remain less understood in terms of improvement of psychosocial outcomes. The system has been considered to provide flexibility and independence by the patients and their caregivers. The workload required to use this system is perceived as a burden by the patients who decrease the use of auto-mode functionality over time.

Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, Rand L, Siebert C (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Eng J Med 329(14):977–986. https://doi.org/10.1056/NEJM199309303291401CrossRef

Stone JY, Haviland N, Bailey TS (2018) Review of a commercially available hybrid closed-loop insulin-delivery system in the treatment of Type 1 diabetes. Ther Deliv 9(2):77–87. https://doi.org/10.4155/tde-2017-0099CrossRefPubMed

Ruiz JL, Sherr JL, Cengiz E, Carria L, Roy A, Voskanyan G, Tamborlane WV, Weinzimer SA (2012) Effect of insulin feedback on closed-loop glucose control: a crossover study. J Diabetes Sci Technol 6(5):1123–1130. https://doi.org/10.1177/193229681200600517CrossRefPubMedPubMedCentral

Garg SK, Weinzimer SA, Tamborlane WV, Buckingham BA, Bode BW, Bailey TS, Brazg RL, Ilany J, Slover RH, Anderson SM, Bergenstal RM, Grosman B, Roy A, Cordero TL, Shin J, Lee SW, Kaufman FR (2017) Glucose outcomes with the in-home use of a hybrid closed-loop insulin delivery system in adolescents and adults with type 1 diabetes. Diabetes Technol Ther 19(3):155–163. https://doi.org/10.1089/dia.2016.0421CrossRefPubMedPubMedCentral

Messer LH, Forlenza GP, Sherr JL, Wadwa RP, Buckingham BA, Weinzimer SA, Maahs DM, Slover RH (2018) Optimizing hybrid closed-loop therapy in adolescents and emerging adults using the MiniMed 670G system. Diabetes Care 41(4):789–796. https://doi.org/10.2337/dc17-1682CrossRefPubMedPubMedCentral

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 151(4):W65-94. https://doi.org/10.7326/0003-4819-151-4-200908180-00136CrossRefPubMed

Abraham MB, de Bock M, Smith GJ, Dart J, Fairchild JM, King BR, Ambler GR, Cameron FJ, McAuley SA, Keech AC, Jenkins A, Davis EA, O’Neal DN, Jones TW, Australian Juvenile Diabetes Research Fund Closed-Loop Research group (2021) Effect of a hybrid closed-loop system on glycemic and psychosocial outcomes in children and adolescents with type 1 diabetes: a randomized clinical trial. JAMA Pediatr 175(12):1227–1235. https://doi.org/10.1001/jamapediatrics.2021.3965CrossRef

Adams RN, Tanenbaum ML, Hanes SJ, Ambrosino JM, Ly TT, Maahs DM, Naranjo D, Walders-Abramson N, Weinzimer SA, Buckingham BA, Hood KK (2018) Psychosocial and human factors during a trial of a hybrid closed loop system for type 1 diabetes management. Diabetes Technol Ther 20(10):648–653. https://doi.org/10.1089/dia.2018.0174CrossRefPubMed

Beato-Víbora Pilar I, Gallego-Gamero F, Lázaro-Martín L, Romero-Pérez MdM, Arroyo-Díez FJ (2020) Prospective analysis of the impact of commercialized hybrid closed-loop system on glycemic control, glycemic variability, and patient-related outcomes in children and adults: a focus on superiority over predictive low-glucose suspend technology. Diabetes Technol Ther 22(12):912–919. https://doi.org/10.1089/dia.2019.0400CrossRefPubMed

10.

Bergenstal RM, Garg S, Weinzimer SA, Buckingham BA, Bode BW, Tamborlane WV, Kaufman FR (2016) Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. JAMA 316(13):1407–1408. https://doi.org/10.1001/jama.2016.11708CrossRefPubMed

11.

Bergenstal RM, Nimri R, Beck RW, Criego A, Laffel L, Schatz D, Battelino T, Danne T, Weinzimer SA, Sibayan J, Johnson ML, Bailey RJ, Calhoun P, Carlson A, Isganaitis E, Bello R, Albanese-O’Neill A, Dovc K, Biester T, Weyman K, Hood K, Phillip M, for the FLAIR Study Group (2021) A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial. Lancet 397(10270):208–219CrossRefPubMedCentral

12.

Berget C, Messer LH, Vigers T, Frohnert BI, Pyle L, Wadwa RP, Driscoll KA, Forlenza GP (2020) Six months of hybrid closed loop in the real-world: an evaluation of children and young adults using the 670G system. Pediatr Diabetes 21(2):310–318. https://doi.org/10.1111/pedi.12962CrossRefPubMedPubMedCentral

13.

Berget C, Akturk HK, Messer LH, Vigers T, Pyle L, Snell-Bergeon J, Driscoll KA, Forlenza GP (2021) Real-world performance of hybrid closed loop in youth, young adults, adults and older adults with type 1 diabetes: Identifying a clinical target for hybrid closed-loop use. Diabetes Obes Metab 23(9):2048–2057. https://doi.org/10.1111/dom.14441CrossRefPubMed

14.

Cobry EC, Hamburger E, Jaser SS (2020) Impact of the hybrid closed-loop system on sleep and quality of life in youth with type 1 diabetes and their parents. Diabetes Technol Ther 22(11):794–800. https://doi.org/10.1089/dia.2020.0057CrossRefPubMedPubMedCentral

15.

Cordero TL, Garg SK, Brazg R, Bailey TS, Shin J, Lee SW, Kaufman FR (2017) The effect of prior continuous glucose monitoring use on glycemic outcomes in the pivotal trial of the MiniMed™ 670G Hybrid closed-loop system. Diabetes Technol Ther 19(12):749–752. https://doi.org/10.1089/dia.2017.0208CrossRefPubMed

16.

de Bock M, Dart J, Roy A, Davey R, Soon W, Berthold C, Retterath A, Grosman B, Kurtz N, Davis E, Jones T (2017) Exploration of the performance of a hybrid closed loop insulin delivery algorithm that includes insulin delivery limits designed to protect against hypoglycemia. J Diabetes Sci Technol 11(1):68–73. https://doi.org/10.1177/1932296816668876CrossRefPubMed

17.

de Bock M, Dart J, Hancock M, Smith G, Davis EA, Jones TW (2018) Performance of Medtronic hybrid closed-loop iterations. results from a randomized trial in adolescents with type 1 diabetes. Diabetes Technol Ther 20(10):693–697. https://doi.org/10.1089/dia.2018.0161

18.

Dominguez-Riscart J, Buero-Fernandez N, Garcia-Zarzuela A, Marmolejo-Franco FA, Perez-Guerrero AC, Lechuga-Sancho AM (2021) Hybrid closed-loop system achieves optimal perioperative glycemia in a boy with type 1 diabetes: a case report. Front Pediatr 9:625390. https://doi.org/10.3389/fped.2021.625390

19.

Duffus SH, Ta’ani ZA, Slaughter JC, Niswender KD, Gregory JM (2020) Increased proportion of time in hybrid closed-loop “Auto Mode” is associated with improved glycaemic control for adolescent and young patients with adult type 1 diabetes using the MiniMed 670G insulin pump. Diabetes Obes Metab 22(4):688–693. https://doi.org/10.1111/dom.13912CrossRefPubMed

20.

Forlenza GP, Pinhas-Hamiel O, Liljenquist DR, Shulman DI, Bailey TS, Bode BW, Wood MA, Buckingham BA, Kaiserman KB, Shin J, Huang S, Lee SW, Kaufman FR (2019) Safety evaluation of the MiniMed 670G system in children 7–13 years of age with type 1 diabetes. Diabetes Technol Ther 21(1):11–19. https://doi.org/10.1089/dia.2018.0264CrossRefPubMedPubMedCentral

21.

Forlenza GP, Ekhlaspour L, DiMeglio LA, Fox LA, Rodriguez H, Shulman DI, Kaiserman KB, Liljenquist DR, Shin J, Lee SW, Buckingham BA (2022) Glycemic outcomes of children 2–6 years of age with type 1 diabetes during the pediatric MiniMed™ 670G system trial. Pediatr Diabetes 23(3):324–329. https://doi.org/10.1111/pedi.13312CrossRefPubMedPubMedCentral

22.

Nally LM, Wagner J, Sherr J, Tichy E, Weyman K, Ginley MK, Zajac K, Desousa M, Shabanova V, Petry NM, Tamborlane WV, Van Name M (2021) A Pilot study of youth with type 1 diabetes initiating use of a hybrid closed-loop system while receiving a behavioral economics intervention. Endocr Pract 27(6):545–551. https://doi.org/10.1016/j.eprac.2020.11.017CrossRefPubMed

23.

Petrovski G, Al Khalaf F, Hussain K, Campbell J (2018) Optimizing a hybrid closed loop system in type 1 diabetes: a case report. Diabetes Ther 9:2173–2177. https://doi.org/10.1007/s13300-018-0473-6CrossRefPubMedPubMedCentral

24.

Petrovski G, Al Khalaf F, Campbell J, Hussain K, Fisher H, Umer F (2020) Glucose control during Ramadan fasting in a teenager with type 1 diabetes on MiniMed 670G hybrid closed-loop system. Acta Diabetol 57(1):105–107. https://doi.org/10.1007/s00592-019-01414-6CrossRefPubMed

25.

Petrovski G, Khalaf FA, Campbel J, Fisher H, Umer F, Hussain K (2020) 10-Day structured initiation protocol from multiple daily injection to hybrid closed-loop system in children and adolescents with type 1 diabetes. Acta Diabetol 57(6):681–687. https://doi.org/10.1007/s00592-019-01472-wCrossRefPubMedPubMedCentral

26.

Petrovski G, Al Khalaf F, Campbell J, Umer F, Almajaly D, Hamdan M, Hussain K (2021) One-year experience of hybrid closed-loop system in children and adolescents with type 1 diabetes previously treated with multiple daily injections: drivers to successful outcomes. Acta Diabetol 58(2):207–213. https://doi.org/10.1007/s00592-020-01607-4CrossRefPubMed

27.

Petrovski G, Campbell J, Almajali D, Al Khalaf F, Hussain K (2021) Successful initiation of hybrid closed-loop system using virtual pump training program in a teenager with type 1 diabetes previously treated with multiple daily injections. J Diabetes Sci Technol 15(6):1394–1398. https://doi.org/10.1177/1932296820950753CrossRefPubMed

28.

Roberts A, Fried L, Dart J, de Bock M, Fairchild J, King B, Ambler GR, Cameron F, McAuley SA, Keech AC, Jenkins A, O Neal DN, Davis EA, Jones TW, Abraham MB, Australian JDRF Closed Loop Research Group (2022) Hybrid closed-loop therapy with a first-generation system increases confidence and independence in diabetes management in youth with type 1 diabetes. Diabet Med 39(9):e14907. https://doi.org/10.1111/dme.14907

29.

Salehi P, Roberts AJ, Kim GJ (2019) Efficacy and safety of real-life usage of MiniMed 670G automode in children with type 1 diabetes less than 7 years old. Diabetes Technol Ther 21(8):448–451. https://doi.org/10.1089/dia.2019.0123CrossRefPubMed

30.

Stone PM, Agrawal P, Chen X, Liu M, Shin J, Cordero TL, Kaufman FR (2018) Retrospective analysis of 3-month real-world glucose data after the MiniMed 670G system commercial launch. Diabetes Technol Ther 20(10):689–692. https://doi.org/10.1089/dia.2018.0202CrossRefPubMed

31.

Varimo T, Pulkkinen MA, Hakonen E, Hero M, Miettinen PJ, Tuomaala AK (2021) First year on commercial hybrid closed-loop system-experience on 111 children and adolescents with type 1 diabetes. Pediatr Diabetes 22(6):909–915. https://doi.org/10.1111/pedi.13235CrossRefPubMed

32.

Tornese G, Ceconi V, Monasta L, Carletti C, Faleschini E, Barbi E (2020) Glycemic control in type 1 diabetes mellitus during covid-19 quarantine and the role of in-home physical activity. Diabetes Technol Ther 22(6):462–467. https://doi.org/10.1089/dia.2020.0169CrossRefPubMed

33.

von dem Berge T, Remus K, Biester S, Reschke F, Klusmeier B, Adolph K, Holtdirk A, Thomas A, Kordonouri O, Danne T, Biester T (2022) In-home use of a hybrid closed loop achieves time-in-range targets in preschoolers and school children: Results from a randomized, controlled, crossover trial. Diabetes Obes Metab 24(7):1319–1327. https://doi.org/10.1111/dom.14706CrossRef

34.

Wood MA, Shulman DI, Forlenza GP, Bode BW, Pinhas-Hamiel O, Buckingham BA, Kaiserman KB, Liljenquist DR, Bailey TS, Shin J, Huang S, Chen X, Cordero TL, Lee SW, Kaufman FR (2018) In-clinic evaluation of the MiniMed 670G system “suspend before low” feature in children with type 1 diabetes. Diabetes Technol Ther 20(11):731–737. https://doi.org/10.1089/dia.2018.0209CrossRefPubMed

35.

Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, Bosi E, Buckingham BA, Cefalu WT, Close KL, Cobelli C, Dassau E, DeVries JH, Donaghue KC, Dovc K, Doyle FJ 3rd, Garg S, Grunberger G, Heller S, Heinemann L, Hirsch IB, Hovorka R, Jia W, Kordonouri O, Kovatchev B, Kowalski A, Laffel L, Levine B, Mayorov A, Mathieu C, Murphy HR, Nimri R, Nørgaard K, Parkin CG, Renard E, Rodbard D, Saboo B, Schatz D, Stoner K, Urakami T, Weinzimer SA, Phillip M (2019) Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care 42(8):1593–1603. https://doi.org/10.2337/dci19-0028CrossRefPubMedPubMedCentral

36.

Bergenstal RM, Nimri R, Beck RW, Criego A, Laffel L, Schatz D, Battelino T, Danne T, Weinzimer SA, Sibayan J, Johnson ML, Bailey RJ, Calhoun P, Carlson A, Isganaitis E, Bello R, Albanese-O'Neill A, Dovc K, Biester T, Weyman K, Hood K, Phillip M, FLAIR Study Group (2021) A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial. Lancet 16;397(10270):208–219. https://doi.org/10.1016/S0140-6736(20)32514-9

37.

Collyns OJ, Meier RA, Betts ZL, Chan DSH, Frampton C, Frewen CM, Hewapathirana NM, Jones SD, Roy A, Grosman B, Kurtz N, Shin J, Vigersky RA, Wheeler BJ, de Bock MI (2021) Improved glycemic outcomes with medtronic minimed advanced hybrid closed-loop delivery: results from a randomized crossover trial comparing automated insulin delivery with predictive low glucose suspend in people with type 1 diabetes. Diabetes Care 44(4):969–975. https://doi.org/10.2337/dc20-2250CrossRefPubMed

38.

Silva JD, Lepore G, Battelino T, Arrieta A, Castañeda J, Grossman B, Shin J, Cohen O (2022) Real-world performance of the MiniMed™ 780G System: first report of outcomes from 4120 users. Diabetes Technol Ther 24(2):113–119. https://doi.org/10.1089/dia.2021.0203CrossRefPubMedPubMedCentral

39.

Arrieta A, Battelino T, Scaramuzza AE, Da Silva J, Castañeda J, Cordero TL, Shin J, Cohen O (2022) Comparison of MiniMed 780G system performance in users aged younger and older than 15 years: evidence from 12 870 real-world users. Diabetes Obes Metab 24(7):1370–1379. https://doi.org/10.1111/dom.14714CrossRefPubMedPubMedCentral

40.

Brown SA, Kovatchev BP, Raghinaru D, Lum JW, Buckingham BA, Kudva YC, Laffel LM, Levy CJ, Pinsker JE, Wadwa RP, Dassau E, Doyle FJ 3rd, Anderson SM, Church MM, Dadlani V, Ekhlaspour L, Forlenza GP, Isganaitis E, Lam DW, Kollman C, Beck RW, iDCL Trial Research Group (2019) Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes. N Engl J Med 381(18):1707–1717. https://doi.org/10.1056/NEJMoa1907863CrossRef

41.

Breton MD, Kanapka LG, Beck RW, Ekhlaspour L, Forlenza GP, Cengiz E, Schoelwer M, Ruedy KJ, Jost E, Carria L, Emory E, Hsu LJ, Oliveri M, Kollman CC, Dokken BB, Weinzimer SA, DeBoer MD, Buckingham BA, Cherñavvsky D, Wadwa RP; iDCL Trial Research Group (2020) A randomized trial of closed-loop control in children with type 1 diabetes. N Engl J Med 383(9):836–845. https://doi.org/10.1056/NEJMoa2004736CrossRef

42.

Kanapka LG, Wadwa RP, Breton MD, Ruedy KJ, Ekhlaspour L, Forlenza GP, Cengiz E, Schoelwer MJ, Jost E, Carria L, Emory E, Hsu LJ, Weinzimer SA, DeBoer MD, Buckingham BA, Oliveri M, Kollman C, Dokken BB, Cherñavvsky D, Beck RW; iDCL Trial Research Group (2021) Extended use of the control-IQ closed-loop control system in children with type 1 diabetes. Diabetes Care 44(2):473–478. https://doi.org/10.2337/dc20-1729CrossRef

43.

Breton MD, Kovatchev BP (2021) One year real-world use of the control-IQ advanced hybrid closed-loop technology. Diabetes Technol Ther 23(9):601–608. https://doi.org/10.1089/dia.2021.0097CrossRefPubMedPubMedCentral

44.

Kariyawasam D, Morin C, Casteels K, Le Tallec C, Sfez A, Godot C, Huneker E, Garrec N, Benhamou PY, Polak M, Charpentier G, Franc S, Beltrand J (2022) Hybrid closed-loop insulin delivery versus sensor-augmented pump therapy in children aged 6–12 years: a randomised, controlled, cross-over, non-inferiority trial. Lancet Digit Health 4(3):e158–e168. https://doi.org/10.1016/S2589-7500(21)00271-5CrossRefPubMed

45.

Ware J, Boughton CK, Allen JM, Wilinska ME, Tauschmann M, Denvir L, Thankamony A, Campbell FM, Wadwa RP, Buckingham BA, Davis N, DiMeglio LA, Mauras N, Besser REJ, Ghatak A, Weinzimer SA, Hood KK, Fox DS, Kanapka L, Kollman C, Sibayan J, Beck RW, Hovorka R; DAN05 Consortium (2022) Cambridge hybrid closed-loop algorithm in children and adolescents with type 1 diabetes: a multicentre 6-month randomised controlled trial. Lancet Digit Health 4(4):e245–e255. https://doi.org/10.1016/S2589-7500(22)00020-6CrossRef

46.

Tauschmann M, Thabit H, Bally L, Allen JM, Hartnell S, Wilinska ME, Ruan Y, Sibayan J, Kollman C, Cheng P, Beck RW, Acerini CL, Evans ML, Dunger DB, Elleri D, Campbell F, Bergenstal RM, Criego A, Shah VN, Leelarathna L, Hovorka R; APCam11 Consortium (2018) Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial. Lancet 392(10155):1321–1329. https://doi.org/10.1016/S0140-6736(18)31947-0. Erratum. In: Lancet 2018;392(10155):1310CrossRef

47.

Ware J, Allen JM, Boughton CK, Wilinska ME, Hartnell S, Thankamony A, de Beaufort C, Schierloh U, Fröhlich-Reiterer E, Mader JK, Kapellen TM, Rami-Merhar B, Tauschmann M, Nagl K, Hofer SE, Campbell FM, Yong J, Hood KK, Lawton J, Roze S, Sibayan J, Bocchino LE, Kollman C, Hovorka R; KidsAP Consortium (2022) Randomized trial of closed-loop control in very young children with type 1 diabetes. N Engl J Med 386(3):209–219. https://doi.org/10.1056/NEJMoa2111673CrossRef

48.

Brown SA, Forlenza GP, Bode BW, Pinsker JE, Levy CJ, Criego AB, Hansen DW, Hirsch IB, Carlson AL, Bergenstal RM, Sherr JL, Mehta SN, Laffel LM, Shah VN, Bhargava A, Weinstock RS, MacLeish SA, DeSalvo DJ, Jones TC, Aleppo G, Buckingham BA, Ly TT; Omnipod 5 Research Group (2021) Multicenter trial of a tubeless, on-body automated insulin delivery system with customizable glycemic targets in pediatric and adult participants with type 1 diabetes. Diabetes Care 44(7):1630–1640. https://doi.org/10.2337/dc21-0172CrossRef

49.

Messer LH, Berget C, Vigers T, Pyle L, Geno C, Wadwa RP, Driscoll KA, Forlenza GP (2020) Real world hybrid closed-loop discontinuation: Predictors and perceptions of youth discontinuing the 670G system in the first 6 months. Pediatr Diabetes 21(2):319–327. https://doi.org/10.1111/pedi.12971CrossRefPubMedPubMedCentral

50.

Lal RA, Basina M, Maahs DM, Hood K, Buckingham B, Wilson DM (2019) One year clinical experience of the first commercial hybrid closed-loop system. Diabetes Care 42(12):2190–2196. https://doi.org/10.2337/dc19-0855CrossRefPubMedPubMedCentral

51.

Roze S, Buompensiere MI, Ozdemir Z, de Portu S, Cohen O (2021) Cost-effectiveness of a novel hybrid closed-loop system compared with continuous subcutaneous insulin infusion in people with type 1 diabetes in the UK. J Med Econ 24(1):883–890. https://doi.org/10.1080/13696998.2021.193970CrossRefPubMed

Titel: Safety, metabolic and psychological outcomes of Medtronic MiniMed 670G in children, adolescents and young adults: a systematic review
verfasst von: Chiara Mameli
Giulia Marie Smylie
Alessio Galati
Biagio Rapone
Roque Cardona-Hernandez
Gianvincenzo Zuccotti
Maurizio Delvecchio
Publikationsdatum: 21.02.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Pediatrics / Ausgabe 5/2023
Print ISSN: 0340-6199
Elektronische ISSN: 1432-1076
DOI: https://doi.org/10.1007/s00431-023-04833-4

Neu im Fachgebiet Pädiatrie

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Frühe Hypertonie erhöht späteres kardiovaskuläres Risiko

16.05.2024 Arterielle Hypertonie in der Pädiatrie Nachrichten

Wie wichtig es ist, pädiatrische Patienten auf Bluthochdruck zu screenen, zeigt eine kanadische Studie: Hypertone Druckwerte in Kindheit und Jugend steigern das Risiko für spätere kardiovaskuläre Komplikationen.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Safety, metabolic and psychological outcomes of Medtronic MiniMed 670G in children, adolescents and young adults: a systematic review

Abstract

Neu im Fachgebiet Pädiatrie

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

ADHS-Medikation erhöht das kardiovaskuläre Risiko

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

Frühe Hypertonie erhöht späteres kardiovaskuläres Risiko

Update Pädiatrie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2023

Maternal smoking during pregnancy and birthweight on the third generation: results from two birth cohort studies

Deep cervical abscesses in children: efficacy of the cefotaxime–rifampicin combination

Advances in targeted therapy for pulmonary arterial hypertension in children

Temporal trend and factors associated with post-endoscopic retrograde cholangiopancreatography pancreatitis in children in the USA: a nationwide, retrospective cohort study

Risk factors of brain abscess in neonatal meningitis: a propensity score–matched study

Assessment of quality of life after laparoscopic GERD surgery in children: a prospective study

Neu im Fachgebiet Pädiatrie

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

ADHS-Medikation erhöht das kardiovaskuläre Risiko

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

Frühe Hypertonie erhöht späteres kardiovaskuläres Risiko

Update Pädiatrie